{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:59:11Z","timestamp":1769993951867,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.virol.2024.110341","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:10:17Z","timestamp":1733195417000},"page":"110341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes"],"prefix":"10.1016","volume":"603","author":[{"given":"Yunus","family":"Yukselten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edidiong","family":"Akang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PeiYi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110341_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00636-22","article-title":"Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compound","volume":"96","author":"Anang","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00793-17","article-title":"Pace of coreceptor tropism switch in HIV-1-Infected individuals after recent infection","volume":"91","author":"Arif","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","article-title":"Clinical pharmacology in HIV therapy","volume":"14","author":"Atta","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol. : CJASN"},{"key":"10.1016\/j.virol.2024.110341_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110341_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2012.01.002","article-title":"Is there a future for antiviral fusion inhibitors?","volume":"2","author":"Berkhout","year":"2012","journal-title":"Current opinion in virology"},{"issue":"5","key":"10.1016\/j.virol.2024.110341_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41573-023-00205-7","article-title":"The landscape and market for HIV therapies","volume":"23","author":"Bowe","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.virol.2024.110341_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/COH.0000000000000469","article-title":"Fostemsavir: a new CD4 attachment inhibitor","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2024.110341_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100955","article-title":"Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide","volume":"68","author":"Ce\u00f1a-Diez","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.virol.2024.110341_bib9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/ar4002735","article-title":"Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist","volume":"47","author":"Courter","year":"2014","journal-title":"Accounts Chem. Res."},{"key":"10.1016\/j.virol.2024.110341_bib10","series-title":"Medical Genetics Summaries","article-title":"Maraviroc therapy and CCR5 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.virol.2024.110341_bib11","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"18","key":"10.1016\/j.virol.2024.110341_bib12","doi-asserted-by":"crossref","first-page":"e00831","DOI":"10.1128\/JVI.00831-17","article-title":"Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition","volume":"91","author":"Ding","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.virol.2024.110341_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.omtn.2018.09.003","article-title":"HIV entry and its inhibition by bifunctional antiviral proteins","volume":"13","author":"Falkenhagen","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.virol.2024.110341_bib14","volume":"vol. 120","author":"Fritschi","year":"2023"},{"key":"10.1016\/j.virol.2024.110341_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28638-w","article-title":"Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation","volume":"8","author":"Humpol\u00ed\u010dkov\u00e1","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2024.110341_bib16","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110341_bib17","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110341_bib18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.virol.2024.110341_bib19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/v11111012","article-title":"HIV-1 envelope glycoprotein amino acids signatures associated with clade B transmitted\/founder and recent viruses","volume":"11","author":"Kafando","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110341_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126675","article-title":"Effect of HIV infection and antiretroviral therapy on immune cellular functions","volume":"4","author":"Korencak","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.virol.2024.110341_bib21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110341_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110341_bib23","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"HIV 7","author":"Lataillade","year":"2020","journal-title":"The lancet"},{"key":"10.1016\/j.virol.2024.110341_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0000000000001602","article-title":"Viral drug resistance through 48 Weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir","volume":"77","author":"Lataillade","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.virol.2024.110341_bib25","doi-asserted-by":"crossref","first-page":"11013","DOI":"10.1073\/pnas.1832214100","article-title":"A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding","volume":"100","author":"Lin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110341_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-019-1101-y","article-title":"Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET","volume":"568","author":"Lu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110341_bib27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.virol.2024.110341_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110341_bib29","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110341_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.virol.2024.110341_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1054-3589(07)55002-7","article-title":"Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors","volume":"55","author":"Prabakaran","year":"2007","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.virol.2024.110341_bib32","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1038\/s41467-023-42500-2","article-title":"Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir","volume":"14","author":"Pr\u00e9vost","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110341_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00280-20","article-title":"The HIV-1 Env gp120 inner domain shapes the Phe43 cavity and the CD4 binding site","volume":"11","author":"Pr\u00e9vost","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110341_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02452-16","article-title":"Influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to antibody-dependent cell-mediated cytotoxicity responses","volume":"91","author":"Pr\u00e9vost","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib35","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2024.110341_bib36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2165\/00003495-200565130-00002","article-title":"Emerging drug targets for antiretroviral therapy","volume":"65","author":"Reeves","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2024.110341_bib37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","article-title":"Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120","volume":"30","author":"Richard","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.virol.2024.110341_bib38","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides","volume":"72","author":"Rimsky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib39","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib40","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","article-title":"Discovery of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110341_bib41","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/jm034082o","article-title":"Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110341_bib42","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: cell binding and entry","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"10.1016\/j.virol.2024.110341_bib43","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.virol.2024.110341_bib44","doi-asserted-by":"crossref","first-page":"9888","DOI":"10.1128\/JVI.76.19.9888-9899.2002","article-title":"Mutagenic stabilization and\/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110341_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dkt412","article-title":"Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068","volume":"69","author":"Zhou","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2024.110341_bib46","article-title":"Improved pharmacological and structural properties of HIV fusion inhibitor AP3 over enfuvirtide: highlighting advantages of artificial peptide strategy","volume":"5","author":"Zhu","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T13:01:30Z","timestamp":1769950890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224003659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"alternative-id":["S0042682224003659"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110341","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110341"}}